HSP90 for Imaging Malignanices (Solid Tumors) - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be given the study drug, HS-196 by injection up to 36 hours before surgery
- Allow us to use your tissue that is removed for research
- Give blood on the day of the injection, day after injection, 1 week following injection, and 1 month following injection

What is the Condition Being Studied?

Breast, Prostate, and Pancreatic Cancer Imaging

Who Can Participate in the Study?

Adults who are having surgery for:
- Prostate cancer
- pancreatic cancer
- breast cancer

Age Group
Adults

What is Involved?

We are doing this study to see if the study drug, HS-196, is safe and to see if there are any side effects that people may experience while taking it.

HS-196 is a drug which marks cancer cells and it may help doctors see the cancer during and after surgery.

Study Details

Full Title
A Phase I Study of HS-196, an HSP90 Inhibitor-Linked Near Infrared Probe for Detection of Solid Malignancies
Principal Investigator
Protocol Number
IRB: PRO00082272
NCT: NCT03333031
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698